Our Compound

We invented a compound, ANS-858, which is an orally bioavailable, selective, reversible ALDH2 inhibitor. Currently, ANS-858 is in preclinical development.

ANS-858 was selected from over 1000 compounds chemically synthesized as apart of our drug discovery program.

CVT-10216 transp

Molecular binding of our prototype inhibitor with the enzyme ALDH2

Product Pipeline

ANS-858 works to inhibit ALDH2 which reduces self-administration of various addictive chemicals including alcohol, nicotine, cocaine, and opiates. Currently our research focuses on alcohol use disorder.

Indication Product Preclinical Phase 1 Phase 2 Phase 3
Alcohol Use Disorder ANS-858

Smoking Cessation

Opioid Use Disorder

Stimulant Use Disorder

Breaking free from harmful cravings

Addiction is compulsive drug seeking behavior in spite of the negative consequences.

People who develop a substance use disorder commonly also suffer from other mental health disorders, such as anxiety. Our research has demonstrated that inhibition of ALDH2 reduces anxiety-like behavior in multiple models, consistent with its effect on mid-brain dopaminergic neurons. These results indicate that ANS-858 may exhibit anti-drinking and anti-anxiety activity and would be novel more complete addition to existing toolkit of therapies and treatments.

Solving Substance Misuse

Protein ALDH2

X-ray crystal structure of ALDH2